NewLink Genetics (Ebola vaccine) Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • Asset Purch.
  • Financing Rounds
  • 1

NewLink Genetics (Ebola vaccine) General Information

Description

Portfolio of Ebola vaccine. The vaccine candidate, called rVSV-EBOV, was originally developed by the Public Health Agency of Canada. It is currently being evaluated in phase-I clinical trials.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Acquirer
Merck & Co.
Primary Office
  • Ames, IA
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

NewLink Genetics (Ebola vaccine) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore NewLink Genetics (Ebola vaccine)‘s full profile, request access.

Request a free trial

NewLink Genetics (Ebola vaccine) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore NewLink Genetics (Ebola vaccine)‘s full profile, request access.

Request a free trial